TABLE 2.

Summary of clinical trials of ginsenosides interventions in cerebarl ischemic stroke patients.

Gensinosides	Model	Sample sizes	Inclusion criteria	Evaluaive critera	Results	References
Rd	Acute ischaemic stroke	Ginsenoside Rd group (n = 290) placebo group (n = 96)	1) 18–75 years of age; 2) had received a clinical diagnosis of primary acute ischaemic stroke and were able to receive the study drug within 72 h after the onset of symptoms; 3) had a score of 5–22 on the NIHSS	NIHSS BI	Ginsenoside Rd improved the NIHSS and mRs scores, and had an acceptable adverse event profile.	Liu et al. (2012)
Rd	Acute ischaemic stroke	Ginsenoside-Rd 10 mg (n = 65) ginsenoside-Rd 20 mg (n = 67) placebo group (n = 67)	1) between 18 and 75 years of age; 2) had a clinical diagnosis of primary acute ischaemic stroke with an onset of the first episode within the previous 72 h; 3) had a score of 5–22 on the NIHSS	NIHSS BI mRs	Ginsenoside Rd improved NIHSS scores at 15 days, no significance of BI and mRs scores at 15 and 90 days.	Liu et al. (2009)

NIHSS, national institutes of health stroke scale; mRs, modified Rankin scalel; BI, barthel index.